Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.135,78 -943,92 (-2,48%) EUR/USD
1,0635 -0,0011 (-0,11%) Bitcoin EUR
58.404,54 +387,00 (+0,67%) CMC Crypto 200
1.284,80 +399,26 (+43,77%)
Cara Therapeutics, Inc. (0HTC.L)
| Chiusura precedente | 0,7348 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 18.632 |
| Capitalizzazione | 274.805 |
| Beta (5 anni mensile) | 0,70 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8000 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireCara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Approval triggers $1.5 million milestone payment to CaraSTAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA® IV Injection Syringe for the
- GlobeNewswire
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:00 a.m. EDT in New York, NY. A webcast of the presentation can be accessed unde
- GlobeNewswire
Cara Therapeutics Reports Second Quarter 2023 Financial Results
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS proposed rule suggests additional funding for TDAPA-designated products in existing functional category; final rule expected in 4Q23 – – Three late-stage oral difelikefalin clinical programs tracking to plan; Internal readout of Part A of K
